DPP4 and Cognitive impairment: In this study, we showed that the DPP-4 inhibitor, linagliptin, improved cognitive impairment, reduced oxidative stress, and suppressed microglial activation in streptozotocin (STZ)-induced diabetic mice, which could evaluate the effect of DPP-4 inhibitor independently of glucose-lowering.